| An update on the clinical consequences of polypharmacy in older adults: a narrative review |
48 |
| An update on the safety of SGLT2 inhibitors |
28 |
| Safety and tolerability of available urate-lowering drugs: a critical review |
20 |
| Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis |
17 |
| The safety of gliptins : updated data in 2018 |
17 |
| Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program |
16 |
| Anakinra for the treatment of rheumatoid arthritis: a safety evaluation |
16 |
| Drug-drug interactions as a result of co-administering Delta(9)-THC and CBD with other psychotropic agents |
15 |
| Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment |
15 |
| Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings |
14 |
| Statin drug interactions and related adverse reactions: an update |
14 |
| The economic burden of preventable adverse drug reactions: a systematic review of observational studies |
14 |
| Androgenetic alopecia; drug safety and therapeutic strategies |
14 |
| The efficacy and safety of amifostine for the acute radiation syndrome |
13 |
| The role of antimicrobial treatment during pregnancy on the neonatal gut microbiome and the development of atopy, asthma, allergy and obesity in childhood |
11 |
| The safety of apatinib for the treatment of gastric cancer |
11 |
| A narrative review of the safety concerns of deprescribing in older adults and strategies to mitigate potential harms |
11 |
| An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency |
11 |
| Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice |
10 |
| The efficacy and safety of memantine for the treatment of Alzheimer's disease |
10 |
| Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder |
9 |
| Optimal management of patients with hepatocellular carcinoma treated with lenvatinib |
9 |
| The safety of available treatment options for iron-deficiency anemia |
9 |
| The safety of treatment options for acute bacterial skin and skin structure infections |
9 |
| The safety of bortezomib for the treatment of multiple myeloma |
9 |
| Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data |
8 |
| Proton pump inhibitors, adverse events and increased risk of mortality |
8 |
| Alcohol addiction - the safety of available approved treatment options |
8 |
| Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms |
8 |
| Muscle and statins: from toxicity to the nocebo effect |
8 |
| Human organotypic bioconstructs from organ-on-chip devices for human-predictive biological insights on drug candidates |
8 |
| Safety of direct oral anticoagulants in real-world clinical practice: translating the trials to everyday clinical management |
8 |
| Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta-analysis of randomized controlled trials and observational studies |
8 |
| Antimalarial drugs for treating and preventing malaria in pregnant and lactating women |
8 |
| A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment |
8 |
| The safety of available treatments of male hypogonadism in organic and functional hypogonadism |
7 |
| The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis |
7 |
| Cognitive and mood side effects of lower urinary tract medication |
7 |
| Safety of sugammadex for reversal of neuromuscular block |
7 |
| Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review |
7 |
| Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase (R) |
7 |
| The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma |
7 |
| Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system |
7 |
| Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis |
7 |
| Safety of drugs used for the treatment of Crohn's disease |
7 |
| An update on the problem of osteoporosis in people with epilepsy taking antiepileptic drugs |
7 |
| A narrative review of problems with medicines use in people with dementia |
7 |
| Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis |
7 |
| Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation |
6 |
| The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis |
6 |
